Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Novartis To Launch Five New Biosimilar Drugs By 2020

XTALKS VITALS NEWS

Biosimilar

The company says that the expansion will further reaffirm Sandoz’s commitment to providing less expensive versions of biologic drugs.

Share this!

June 21, 2016 | by Sarah Massey, M.Sc.

Novartis’ generics division, Sandoz, has announced that it plans to push five new biosimilar drugs through the product pipeline all the way to approval by 2020. The company says that the expansion will further reaffirm Sandoz’s commitment to providing less expensive versions of biologic drugs.

Tweet: Novartis’ Sandoz to push five new #biosimilar drugs to approval by 2020 http://ctt.ec/sLUV9+

Sandoz has plans to file applications for marketing approval for 11 biosimilar drugs in both the US and in Europe, by the end of 2017. The company has already reached the half-way point by filing six of the 11 biosimilar applications.

Sandoz’s current biosimilar offerings include Omnitrope (somatropin) and Binocrit (epoetin alfa) in Europe, and Zarxio (filgrastim-sndz) in the US. If all of the company’s biosimilar applications are approved by regulatory agencies, Sandoz may have nearly three times as many products on the market in just four years.

Novartis has also pledged to spend $1 billion on biosimilar manufacturing between 2010 and 2020. In the past six years, the company has already expanded operations at its manufacturing plants in Schaftenau and Kundl, Austria.

Biosimilars are the generic versions of biologic drugs, and are considered to have clinically comparable effects as their branded counterpart. Once the patent-exclusivity period for a given biologic has expired, biosimilars companies are free to develop less-expensive, copy-cat versions.



Investment into biosimilars has been spurred on by the recent patent expirations for top-selling biologics, including Humira and Remicade. While many biosimilars have been long-established on the European market, the US is only just starting to enter the space.

Novartis' Zarxio – a biosimilar of Amgen’s biologic drug, Neupogen – was the first ever biosimilar to win US Food and Drug Administration (FDA) approval in 2015. The regulatory agency has since approved a Remicade biosimilar developed by Celltrion and Pfizer.

Novartis plans to release biosimilar versions of Enbrel, Humira, Neulasta, Remicade, and Rituxan over the next few years. In 2015, those five biologics generated $44 billion in worldwide revenue.

“Biologics have revolutionized treatment of many disabling and life-threatening diseases but far too many people who need these medicines are not able to access them,” said Richard Francis, CEO of Sandoz. “At Sandoz, we are committed to significantly broadening patient access to biologics with a series of major biosimilar launches over the next few years.”


Keywords: Biosimilar, Biologic, FDA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Better Meal Planning for Diabetics Using a Predictive Blood Sugar App

April 21, 2017 - A new app could allow people with type 2 diabetes to make predictions about the impact of a meal on their blood sugar levels, before they even take a bite.

Featured In: Life Science News


Bacterial Biomarkers Could Make Diagnosing Colorectal Cancer Less Invasive

April 20, 2017 - Researchers at The University of Texas Health Science Center at Houston School of Public Health have identified specific strains of gut bacteria which have been associated with colorectal cancer.

Featured In: Life Science News


Weetabix Cereal Sold to Post in £1.4 Billion Deal

April 20, 2017 - The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Electronic Informed Consent: 2017 Industry Survey Results


Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-Time


The Modernization of eCOA Technology for Clinical Trials


Developing a Biological Safety Evaluation


Copyright © 2016-2017 Honeycomb Worldwide Inc.